$RLFTF (Industry related) DD by Wotan (copy) All
Post# of 653
(Total Views: 538)
Posted On: 02/01/2021 12:39:41 AM
$RLFTF (Industry related) DD by Wotan (copy) All uploaded in January... Exciting!!
https://pubmed.ncbi.nlm.nih.gov/?term=vasoact...rt=pubdate
Some replies: Ya-h00
---
"VIP is shown to have important potential effects in the treatment of other lung diseases including Chronic Obstructive Pulmonary Disease ('COPD'), Sarcoidosis, asthma/allergy, and Chronic Respiratory Inflammation Syndrome ('CRIS'). VIP is also known to be active in the brain and NeuroRx plans to explore its potential use in the treatment of Huntington’s Disease, Multiple Sclerosis, and other CNS diseases via our partnership with the nose to brain delivery system developed by Sipnose." S4, p. 173 $BRPA
At the end of the day, aviptadil may likely be used more for CNS diseases than pulmonary diseases
Dude, this is kind of amazing. I am trying to post the findings on here as excerpts and they appear to be getting deleted.
In the S-4 they said that they were allowed by the FDA to use previous findings over the last 20 years. I am going to guess this has something to do with that?
Addiction, depression, anxiety are all covered in the first 4.
It stretches from Headache to Cancer....
Very impressive how much interest there is in VIP. Particularly intriguing is article #5 on VIP and affective disorders: "Negative correlation were found between VIP levels and symptoms of anxiety (
(p=.008) and depression (p=0.001). Study was done in 37 healthy females. This means that VIP could be helpful in these disorders, especially in CV-19 "longhaulers" who have symptoms long after they overcome the infection. This should be the next Dr Javitt "TO DO STUDY". There are already thousands of patients with these problems. Forget about the limited # of patients with bipolar disease and risk of suicide.
WOW
https://pubmed.ncbi.nlm.nih.gov/?term=vasoact...rt=pubdate
Some replies: Ya-h00
---
"VIP is shown to have important potential effects in the treatment of other lung diseases including Chronic Obstructive Pulmonary Disease ('COPD'), Sarcoidosis, asthma/allergy, and Chronic Respiratory Inflammation Syndrome ('CRIS'). VIP is also known to be active in the brain and NeuroRx plans to explore its potential use in the treatment of Huntington’s Disease, Multiple Sclerosis, and other CNS diseases via our partnership with the nose to brain delivery system developed by Sipnose." S4, p. 173 $BRPA
At the end of the day, aviptadil may likely be used more for CNS diseases than pulmonary diseases
Dude, this is kind of amazing. I am trying to post the findings on here as excerpts and they appear to be getting deleted.
In the S-4 they said that they were allowed by the FDA to use previous findings over the last 20 years. I am going to guess this has something to do with that?
Addiction, depression, anxiety are all covered in the first 4.
It stretches from Headache to Cancer....
Very impressive how much interest there is in VIP. Particularly intriguing is article #5 on VIP and affective disorders: "Negative correlation were found between VIP levels and symptoms of anxiety (
(p=.008) and depression (p=0.001). Study was done in 37 healthy females. This means that VIP could be helpful in these disorders, especially in CV-19 "longhaulers" who have symptoms long after they overcome the infection. This should be the next Dr Javitt "TO DO STUDY". There are already thousands of patients with these problems. Forget about the limited # of patients with bipolar disease and risk of suicide.
WOW
(1)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ